Most people overestimate how transmissible HSV is — especially with protection. Here's what the actual data says, explained clearly.
Herpes simplex spreads through direct skin-to-skin contact with the affected area during viral shedding. It does not travel through air, survive on surfaces for more than a few seconds, or spread through shared towels, toilet seats, or casual touch.
The affected area matters. HSV-1 oral spreads through oral contact. HSV-1 or HSV-2 genital spreads through genital contact — or oral-to-genital contact. Transmission requires the virus to meet mucous membrane or broken skin. Intact skin is an effective barrier.
The virus sheds from the skin surface — not from blood or saliva in general. Shedding does not mean visible sores. The virus can be active and transmissible even when there are no symptoms at all. This is called asymptomatic shedding, and it's the most important concept to understand.
HSV lives in the nerve ganglia near the base of the spine. Most of the time it's dormant — inactive and non-transmissible. On some days, it travels to the skin's surface and sheds, whether or not it produces any visible symptoms.
Studies tracking daily swabs from HSV-2 positive individuals found shedding on approximately 15–20% of days without antiviral medication — meaning the virus was detectable on the skin roughly one in six days. With daily valacyclovir, that drops to around 3–5% of days.
Shedding episodes are typically short — often a few hours — and the viral load is usually much lower during asymptomatic shedding than during an active outbreak. Lower viral load means lower transmission risk per contact, even when shedding is happening.
HSV-1 genitally sheds at a significantly lower rate than HSV-2 — roughly half as often. If you have genital HSV-1, your baseline transmission risk is lower to begin with.
These are annual transmission rates for regular couples — not per-act rates. The distinction matters: per-act risk is very low; annual risk accumulates over many contacts across a year. The numbers below reflect HSV-2, which sheds more frequently than genital HSV-1.
For context: The annual risk of a vaccinated person contracting flu from a household contact is estimated at 5–15%. The risk of pregnancy in couples using condoms correctly is ~2% per year. At <1–2%, combined HSV protection puts transmission risk well within the range of risks most people accept in daily life without a second thought.
Daily antiviral therapy — most commonly valacyclovir (Valtrex) at 500mg once daily — works by interfering with the virus's ability to replicate. When the virus tries to travel to the skin surface, the drug suppresses the replication cycle before it gains enough viral load to shed effectively.
Suppressive therapy vs. episodic therapy: Episodic therapy means taking antivirals only when an outbreak occurs, to shorten its duration. Suppressive therapy means taking them every day regardless of symptoms. If your goal is reducing transmission risk to partners, suppressive therapy is required — episodic therapy doesn't reduce asymptomatic shedding.
Valacyclovir is well-tolerated, inexpensive as a generic, and has been in use for over 25 years. It doesn't interact with alcohol in any meaningful way. It's not a cure — the virus remains in the ganglia — but it keeps the virus quiet the vast majority of the time.
One important limitation of condoms: Condoms cover the penis or line the vagina, but HSV can shed from areas not covered — the base of the shaft, the scrotum, inner thighs, or buttocks. Condoms significantly reduce risk but can't eliminate it entirely because they don't cover all skin that may shed. This is why antivirals — which reduce shedding across all skin — are the more complete protection strategy.
The virus reactivates when the immune system is under stress. Common triggers include: physical illness, especially fever; high psychological stress; sleep deprivation; UV exposure (for oral HSV-1); hormonal shifts including menstruation; and friction or irritation in the affected area.
Prodromal symptoms — tingling, itching, or a burning sensation in the affected area — typically appear 12–48 hours before a visible outbreak. Recognizing these early signals gives you time to start episodic antivirals (if not already on suppressive therapy) and to communicate clearly with a partner about contact.
Managing triggers is a legitimate reduction strategy. Most long-term HSV-positive people report that their outbreaks become less frequent over years — partly because the immune system mounts a stronger response over time, and partly because they get better at managing the factors that provoke reactivation.